---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-033463"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:23:18.866385+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioMarin appoints Timothy Walbert to board, expanding size to 12 members

## Summary
- Board increased from 11 to 12 members; Walbert appointed effective February 24, 2025.
- Walbert receives standard independent director compensation including pro rata RSU grant (annual award $400,000).
- No committee assignments at this time; standard indemnification agreement to be entered into.

## SEC filing metadata
- accession: 0001193125-25-033463
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312525033463/0001193125-25-033463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312525033463/d876806d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-033463
- JSON: https://secwatch.observer/filing/0001193125-25-033463.json
- Plain text: https://secwatch.observer/filing/0001193125-25-033463.txt

## Key facts
- Executive change
  Timothy P. Walbert was appointed as Director at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: Director
  source text: the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312525033463/0001193125-25-033463-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.